Samsung Biologics and European pharma company enter major manufacturing deal
The global CDMO has entered into several high-value manufacturing deals this year.
Mergers & deals
Genesis Therapeutics partners with NVIDIA to boost AI-driven drug discovery
Genesis also announced a further investment from NVentures, NVIDIA’s venture capital arm.
AstraZeneca doubles down on US manufacturing with $3.5 billion investment
AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it unveils a $3.5 billion infusion into US sites.
Gifthealth and United Digestive partner for enhanced GI care access
Gifthealth Partners with United Digestive to boost patient access and procedure prep.
Private equity firms GHO and Ampersand acquire Avid Bioservices for $1.1 billion
Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the acquisition of Avid Bioservices.
Axonis raises $115 million to overcome drug resistance in epilepsy
The Boston-based startup Axonis Therapeutics has bagged $115 million in a Series A round to fuel its pipeline of treatments for pain, epilepsy and other conditions.
Radiopharmaceutical CDMO launched by NorthStar Medical Radioisotopes
The US manufacturer NorthStar Medical Radioisotopes has unveiled a Contract Development & Manufacturing (CDMO) facility dedicated to the production and development of medical radioisotopes.
Merck acquires cancer startup in a deal worth up to $1.3 billion
Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair processes.
Seaport Therapeutics closes $225 million Series B to develop neuropsychiatric drugs
The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major depressive disorder and generalized anxiety disorder.
Lundbeck acquires Longboard Pharmaceuticals in $2.6 billion deal
The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.
Innovent and Ask Pharm join forces to commercialize third-generation lung cancer therapy
The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.
SK pharmteco to strengthen small molecule and peptide capacity with $260 million investment
SK Group’s contract development and manufacturing organization (CDMO) arm SK pharmteco is spending $260 million to expand its small molecule and peptide manufacturing muscle in South Korea.
F2G raises $100 million to combat innovation 'paucity' in antifungals
One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.
Creyon Bio secures second patent for AI-powered oligonucleotide engineering
Creyon Bio Inc., a clinical-stage biotechnology company specializing in AI and machine learning-enabled oligonucleotide-based medicines (OBMs), recently announced the issuance of its second US patent.
Seqster and PatientsLikeMe partner to enhance patient data engagement
Seqster and PatientsLikeMe have announced a strategic partnership to integrate real-time electronic health record (EHR) data with patient engagement tools, aiming to significantly improve clinical research and patient outcomes.
UCB advances innovation strategy with $680M divestment deal in China
UCB, a global biopharmaceutical leader, has taken a significant step in refining its strategic focus by divesting its mature neurology and allergy portfolio in China.
SSNL - track and trace
TraceLink and Tecsys partnership: healthcare supply chain with integrated digital solutions
In a strategic move aimed at transforming healthcare supply chains, TraceLink, a leading provider of digital supply chain solutions, has partnered with Tecsys, an industry leader in inventory and warehouse management systems.
Bruker acquires stake in NovAliX, an alliance to revolutionize drug discovery
In a significant move set to reshape the landscape of drug discovery, NovAliX, a leading Contract Research Organization (CRO) specializing in drug development, has entered a strategic partnership with Bruker, a global leader in scientific instruments.
Biologics driving M&A as Agilent snaps up specialist BIOVECTRA for $925 million
As advanced therapies drive increasing market consolidation, the US giant Agilent Technologies has acquired the Canadian contract development and manufacturing organization (CDMO) BIOVECTRA for $925 million.
Keensight Capital supports CatSci for ownership of specialist chromatography provider Reach Separations
CatSci, a UK-based innovation partner for the development of pharmaceutical manufacturing processes, will be expanding its service offering with the acquisition of Reach Separations.
Eli Lilly boosts radiopharmaceuticals focus with $140 million Radionetics partnership
Under the terms of the agreement, Eli Lilly will obtain the exclusive rights to acquire Radionetics Oncology for $1 billion.
ALS treatment PrimeC slows disease progression by 36% phase 2b trial results show
NeuroSense Therapeutics has announced positive phase 2b results for a drug combination designed to treat amyotrophic lateral sclerosis (ALS).
Asahi Kasei's $1.1 billion power move - acquiring Calliditas to dominate global healthcare
In a bold move set to reshape the global healthcare landscape, Asahi Kasei Corp. announced its intent to acquire Swedish drug maker Calliditas Therapeutics AB through a voluntary tender offer.
Swixx BioPharma expands to Latin America through strategic acquisition of Biopas
Swixx BioPharma AG, a platform dedicated to unlocking access to e medicines, has announced its strategic expansion into Latin America.
PrecisionLife and Metrodora Institute spearhead clinical trials for ME/CFS and Long COVID patients
PrecisionLife, an innovative precision medicine company, and Metrodora Institute, a leading US multi-specialty healthcare center, have joined forces.
Walgreens to be used as clinical trial sites focusing on obesity and type 2 diabetes
Walgreens and Boehringer Ingelheim have joined forces in a move to enhance diversity and accessibility in clinical trials, aiming to make participation more inclusive and equitable.
Adragos Pharma - poised to make a lasting impact in the pharmaceutical industry
Adragos Pharma is a contract development and manufacturing organization (CDMO) that provides development and manufacturing services for drug products. It concentrates on small molecule dosage forms including sterile and non-sterile liquids, solids, and...
SimBioSys and General Inception unite to revolutionize cancer drug development
Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.
Bora Pharmaceuticals completes Upsher-Smith acquisition, expanding North American footprint
Bora Pharmaceuticals Co., Ltd. yesterday (April 1) finalized the acquisition of Upsher-Smith Laboratories, Inc., a leading generics manufacturer based in Minnesota, U.S., from its previous owners, Sawai Group Holdings and Sumitomo Corporation of Americas.
Merck announces €300 million investment in new life science facility in Korea
Merck set to invest over €300 million in new production center in South Korea.
Roquette snaps up IFF Pharma Solutions for $2.85 billion
Roquette has acquired the pharma solutions division at International Flavors & Fragrances, in a deal up to $2.85 billion.
Lonza to acquire manufacturing site from Roche in major $1.2 billion deal
Lonza is set to acquire a large-scale manufacturing site from Roche-owned U.S. giant Genentech for $1.2 billion.
Bristol Myers Squibb completes $14 billion acquisition of Karuna Therapeutics from PureTech
Yesterday (March 18) PureTech Health plc announced the completion of the acquisition of its founded entity, Karuna Therapeutics, Inc., by Bristol Myers Squibb for a staggering $14 billion.
Negev Capital fuels psychedelic medicine breakthroughs worldwide with three companies
Venture Capital firm, Negev Capital, holds a portfolio of companies creating neuropsychiatric drugs based on psychedelic molecules.
Florence Healthcare and Slope join forces to address site technology ecosystem demand
Connectivity for research site processes and research has strengthened significantly following a partnership between Florence Healthcare and Slope.
Saama's agreement with Pfizer to fundamentally change drug development processes, helping more people worldwide
Today (February 12) Saama has announced a newly expanded, multi-year agreement with biopharma giant, Pfizer, to help expedite clinical research.
Merck and Quibim partner for next generation of imaging-based diagnostics
Announced today (January 25), Quibim, a company transforming imaging data into actionable predictions of cancer progression and treatment responses, has partnered with Merck KGaA.
Bora Pharmaceuticals expands into the US for the first time with Upsher-Smith acquisition
Bora Pharmaceuticals is set to acquire US pharma manufacturer Upsher-Smith Laboratories for up to $210 million, it says, to fuel global expansion.
Inceptua and Cycle partnership brings hope to patients at the end of the treatment road
Inceptua Group and Cycle Pharmaceuticals partnership will give access to Free Goods Partnership that gets medicine to patients with extremely rare genetic conditions, which they would be unable to access otherwise.
SmartLabs' $48 million funding to accelerate timelines saving up to 2 years in scale-up time
With innovative and flexible lab and manufacturing solutions being a critical success factor in drug development and delivery, SmartLabs, was delighted to announce the raise of $48 million series C financing.
Alliance to improve two complex and critical aspects of drug development and manufacturing
An alliance between KBI Biopharma Inc., and Argonaut Manufacturing Services Inc., has been formed so biopharma clients can receive end-to-end drug substance and drug product manufacturing solutions.
Drug delivery technology provider DelSiTech receives €10 million investment
Clinical-stage drug delivery and development company DelSiTech has made the biggest single financing round in its history with the successful completion of a €10 million deal.
GSK to pump £200 million into UK to boost medicine production and buys Aiolos Bio for $1.1 billion
Pharma giant, GSK, plans to invest £200 million ($253 million) into the UK over the next two years and has acquired Aiolos Bio for $1.1 billion (£870 million).
SGD Pharma to grow significantly in 2024 with investments and package manufacturing
SGD Pharma has announced its goal to become the global market leader in primary pharmaceutical glass packaging.
Evotec to advance drug discovery in collaboration with the Crohn’s & Colitis Foundation
Evotec’s end-to-end integrated research and development platform will be able to advance drug discovery for two drug targets which is why it has joined forces with the Crohn’s & Colitis Foundation.
Partnership puts Israel on the AI and computational science map
AION Labs, the first-of-its-kind venture studio today (January 8) announced its new partnership with Amiti Ventures, a leading early-stage venture capital firm in Israel.
Small molecule drug discovery at center of $37.5 million collaboration deal
Novartis is paying Isomorphic Labs $37.5 million upfront to collaborate on small molecule drug discovery.
BMS buys Karuna Therapeutics for $14 billion in deal that includes schizophrenia treatment
Bristol Myers Squibb has announced it has acquired Karuna Therapeutics, Inc., for a total equity value of $14 billion or $12.7 billion net of estimated cash.
Five decentralized clinical trial organizations raising big VC cash
Decentralized clinical trials (DCTs) are gaining increasing interest as they have the potential to make clinical trial operations quicker, more efficient and more accessible to patients. Check out five DCT organizations that have raised big venture...
The key pharmaceutical trends from 2023 according to industry leaders
The pharmaceutical industry in 2023 has seen many investments, partnerships, acquisitions and more. As the year ends, industry leaders give the biggest trends to look for in 2024, with artificial intelligence being a hot topic.